1. Home
  2. NIM vs EQ Comparison

NIM vs EQ Comparison

Compare NIM & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Select Maturities Municipal Fund

NIM

Nuveen Select Maturities Municipal Fund

HOLD

Current Price

$9.26

Market Cap

114.1M

Sector

Finance

ML Signal

HOLD

EQ

Equillium Inc.

HOLD

Current Price

$2.25

Market Cap

129.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NIM
EQ
Founded
1992
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
114.1M
129.0M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
NIM
EQ
Price
$9.26
$2.25
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.00
AVG Volume (30 Days)
20.8K
252.6K
Earning Date
01-01-0001
05-25-2026
Dividend Yield
3.46%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$41,095,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.93
$0.29
52 Week High
$9.94
$2.70

Technical Indicators

Market Signals
Indicator
NIM
EQ
Relative Strength Index (RSI) 45.62 53.44
Support Level $9.23 $1.60
Resistance Level $9.44 $2.61
Average True Range (ATR) 0.08 0.24
MACD 0.00 -0.01
Stochastic Oscillator 43.75 52.54

Price Performance

Historical Comparison
NIM
EQ

About NIM Nuveen Select Maturities Municipal Fund

Nuveen Select Maturities Municipal Fund is a diversified closed-end management investment company. Its primary investment objective is to provide current income exempt from regular federal income tax, consistent with the preservation of capital. Its secondary investment objective is to enhance portfolio value relative to the municipal bond market through investments in tax-exempt municipal obligations that are underrated or undervalued, or that represent municipal market sectors that are undervalued.

About EQ Equillium Inc.

Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.

Share on Social Networks: